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Cancer is a very heterogeneous disease, and biological
variability adds a further level of complexity, thus limiting
the ability to identify new genes involved in cancer devel-
opment. Oncogenes whose expression levels control cell
aggressiveness are very useful for developing cellular mod-
els that permit differential expression screenings in iso-
genic contexts. HMGA1 protein has this unique property
because it is a master regulator in breast cancer cells that
control the transition from a nontumorigenic epithelial-like
phenotype toward a highly aggressive mesenchymal-like
one. The proteins extracted fromHMGA1-silenced and con-
trol MDA-MB-231 cells were analyzed using label-free shot-
gun mass spectrometry. The differentially expressed pro-
teins were cross-referenced with DNA microarray data
obtained using the same cellular model and the overlapping
genes were filtered for factors linked to poor prognosis in
breast cancer gene expression meta-data sets, resulting in
an HMGA1 protein signature composed of 21 members
(HRS, HMGA1 reduced signature). This signature had a
prognostic value (overall survival, relapse-free survival, and
distant metastasis-free survival) in breast cancer. qRT-
PCR, Western blot, and immunohistochemistry analyses
validated the link of threemembers of this signature (KIFC1,
LRRC59, and TRIP13) with HMGA1 expression levels both in
vitro and in vivo and wound healing assays demonstrated
that these three proteins are involved in modulating tumor
cell motility. Combining proteomic and genomic data with
the aid of bioinformatic tools, our results highlight the po-
tential involvement in neoplastic transformation of a re-
stricted list of factors with an as-yet-unexplored role in
cancer. These factors are druggable targets that could be
exploited for the development of new, targeted therapeutic
approaches in triple-negative breast cancer. Molecular &
Cellular Proteomics 15: 10.1074/mcp.M115.050401, 109–
123, 2016.
Breast cancer is a striking example of tumor heterogeneity.
This feature is one of the main factors impairing the accurate
prognosis and prediction of systemic therapies response, a
fact that is particularly evident for triple-negative breast can-
cers (TNBC)1 (1). Estrogen and progesterone receptor (ER and
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PR), HER2/ERBB2, and Ki67 expression levels together with
tumor–node-metastasis (TNM) staging are the parameters
used to stratify patients and guide therapeutic decisions (2).
With the advent of the genomic era, microarray gene expres-
sion profile analyses have enabled the categorization of
breast cancer into seven main molecular subtypes (luminal A,
luminal B, basal-like, Her2-enriched, normal breast-like, clau-
din-low, and molecular apocrine) (3). In addition to classifica-
tion, microarray data have been used to search for multigene
classifiers constituting molecular signatures with prognostic
and predictive value, and these data can also provide a
deeper understanding of the multiple interconnected altera-
tions occurring during cell transformation (3). However, the
biological heterogeneity of samples often leads to an intrinsic
difficulty in identifying those genes that are relevant for cancer
biology because the ‘real’ tumor-driving genes may be hidden
in the highly variable individual tumor profiles. Indeed, most of
the differentially expressed genes that have been identified
using microarray-based gene expression profiling studies of
patients’ tissues can be classified as “passenger signals,” i.e.
genes whose expression has been altered as a consequence
of the high genomic instability of the cancer cells but that are
not directly involved in the development of the disease (4).
This finding highlights the need to use biological models when
possible to compare the pathological condition versus the
normal one in the same molecular context to determine genes
directly linked to well-defined cancer development stages,
which play a role in cell transformation and could constitute
more robust and accurate biomarkers (5).
HMGA1 (high mobility group A1) proteins, including
HMGA1a and HMGA1b, are architectural transcriptional fac-
tors derived from the alternative splicing of the HMGA1 gene,
whose high expression has been demonstrated to be a hall-
mark of cancer cells (6) and show diagnostic and prognostic
value in several cancers (7). Indeed, these proteins have been
shown to be relevant “hub proteins” with a well-defined on-
cogenic role in cells of different origin (7, 8). In regards to
breast cancer, several experimental results have assigned a
critical role for HMGA1 in driving breast cell transformation.
Most human breast cancer cell lines exhibit higher HMGA1
expression levels with respect to nontransformed cell lines (9,
10). A positive correlation between HMGA1 increased expres-
sion levels and worse breast cancer clinicopathological fea-
tures and prognosis has been established (11, 12); however,
there are also contrasting data showing that in BRCA2-
mutated patients, HMGA1 expression is a good prognostic
factor for breast cancer outcome (13). Moreover, an altera-
tion of HMGA1 expression levels leads to relevant changes
in the tumorigenic properties of breast cancer cell lines.
Indeed, HMGA1 over-expression in nonaggressive, nontu-
morigenic human breast epithelial cells leads to the acqui-
sition of a transformed and aggressive phenotype (10),
whereas HMGA1 silencing in highly aggressive, metastatic
human breast cancer cell lines leads to reversion of the
tumorigenic phenotype, as assessed both by in vitro and in
vivo approaches (9, 12, 14, 15).
HMGA1 proteins exploit pleiotropic mechanisms to drive
breast cancer development and progression. Genome-wide
approaches performed on breast cancer cell lines clearly
demonstrated that HMGA1 proteins influence the expression
of migration- and stemness-related genes, as well as genes
involved in cell proliferation, epithelial-mesenchymal transi-
tion (EMT), and development (10, 12, 15), according to the
well-established activities of HMGA1 in neoplastic transfor-
mation in general (6). Moreover, several experimental results
have highlighted the specific molecular mechanisms influ-
enced by HMGA1 in mammary cell transformation. For in-
stance, HMGA1 proteins inhibit apoptosis by interfering with
p53 function (16), downregulate the DNA repair protein
BRCA1 (17, 18), interfere with nucleotide excision repair (19),
enhance Ras-Raf-MEK-ERK and insulin receptor signaling
(20, 21), interfere with the Hippo pathway by promoting YAP
nuclear localization (22), and regulate the transcription of
miRNAs, such as miRNA-181b, involved in cell cycle control
(23). We previously showed that suppression of HMGA1 ex-
pression in highly aggressive, MDA-MB-231 TNBC cells led to
reversion of the tumoral phenotype. Indeed, HMGA1-silenced
cells acquired an epithelial morphology and cell-cell contact
inhibition, lost self-renewal capacity, and showed reduced
migration, invasion, and metastatic abilities with respect to
control cells (12). Therefore, this unique cellular model en-
ables the comparison of gene and protein expression profiles
of two well-defined conditions, i.e. aggressive versus nonag-
gressive breast cancer cells, in an almost isogenic molecular
context, thereby minimizing “passenger signal” changes and
underlining those genes that are strictly related to the trans-
formation process itself (4).
In this study, by performing shotgun label-free quantitative
proteomics and merging these data with those previously
obtained by gene array (hereafter siHMGA1 data set) (12), we
determined an HMGA1-linked protein molecular signature
composed of 21 factors with prognostic value in breast can-
cer. Among these 21 factors, we focused on three proteins
(KIFC1, LRRC59, and TRIP13) whose involvement in cancer is
largely unknown. We demonstrated (1) that their expression is
linked to HMGA1, both in vitro and in vivo; (2) that their gene
expression levels have prognostic value in terms of overall,
relapse-free, and distant metastasis-free survival (OS, RFS,
complex subunit 3; OS, Overall survival; PGRMC1, Membrane-asso-
ciated progesterone receptor component 1; PR, Progesterone recep-
tor; PRPF4B, Serine/threonine-protein kinase PRP4 homolog; RFS,
Relapse-free survival; RPRD1A, Regulation of nuclear pre-mRNA do-
main-containing protein 1A; RRM2, Ribonucleoside-diphosphate re-
ductase subunit M2; SMC2, Structural maintenance of chromosomes
protein 2; TNM, Tumour-node-metastasis; TOP2A, DNA topoisomer-
ase 2-alpha; TRIP13, Thyroid hormone receptor interactor 13; u-A1,
Upregulated proteins in HMGA1 silenced MDA-MB-231 cells;
WHSC1, Histone-lysine N-methyltransferase NSD2.
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and DMFS, respectively); and (3) that suppression of their
expression in the MDA-MB-231 TNBC cell line significantly
impacts cell motility, suggesting an unexplored role for these
proteins in cancer invasion and metastasis.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatments—Silencing experiments in MDA-MB-
231 cells were performed as previously described (12). Briefly, MDA-
MB-231 cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) containing 100 U/ml penicillin, 100 g/ml streptomycin, 2
mM L-glutamine and 10% tetracycline-free FBS (Euroclone S.p.A.,
Pero (MI), Italy, cat. ECS0182L). The cells were plated at 20–30%
confluence. After 24 h, silencing was performed upon transfecting the
cells with siRNAs (HMGA1 siRNA - siA1_1 and siA1_3 -, KIFC1,
LRRC59, TRIP13 siRNA, or control siRNA - siCTRL -, Eurofins MWG
Operon, Ebersberg, Germany) using LipofectamineTM RNAiMAX rea-
gent (Thermo Fisher Scientific/Invitrogen, Waltham MA) for 72 h ac-
cording to the manufacturer’s recommendations. The experiments
were performed in biological triplicate. The siRNA sequences are
reported in supplemental data. The MDA-MB-231 cell line was kindly
provided by Prof. G. Del Sal (Laboratorio Nazionale CIB, (LNCIB),
Area Science Park, 34149 Trieste, Italy). Total protein concentrations
were quantified after SDS-PAGE analyses followed by Coomassie
blue staining and densitometry (Image Scanner, Amersham Biosci-
ences, now GE Healthcare Europe GmbH, Freiburg, Germany Biosci-
ences, Image Master LabScan v.3.00 software). HMGA1 silencing
was assessed by quantitative Western blot analyses using an anti-
HMGA1 rabbit polyclonal antibody developed in our laboratory. SDS-
PAGE and Western blot analyses were performed in accordance with
conventional methods.
Experimental Design and Statistical Rationale and Proteomic anal-
ysis—The cells were washed twice in PBS and lysed in 2% SDS-
containing buffer including 100 mM DTT and 100 mM Tris-HCl pH 7.8.
Each biological replicate (n  3; HMGA1 silenced cells versus control
cells, see cell culture and treatments) was analyzed in technical
duplicates. The whole cell lysates were processes with MED-FASP
using LysC and trypsin (24). Total protein and total peptides were
quantified as described previously (25). Liquid chromatographic sep-
aration was performed on a C18 reverse phase (12 cm  75 m i.d.)
column packed with 5 m resin that was coupled to a LTQ Orbitrap
mass spectrometer (Thermo Fisher Scientific, Germany) via a nano-
electrospray source (Proxeon Biosystems, now Thermo Fisher Scien-
tific). The LTQ Orbitrap was operated in data-dependent mode with
survey scans acquired at a resolution of 60,000 at m/z 400. For CID
fragmentation, as many as 10 of the most abundant precursor ions
from the survey scan with a charge  2 within a 300–1700 m/z
range were selected. The normalized collision energy was 35. The
dynamic exclusion parameters were 90 s and 5 ppm. The MS2 spec-
tra were acquired in the ion trap. The mass spectrometry (MS) data
were analyzed with MaxQuant software (version 1.2.6.20) using the
Andromeda search engine (26, 27). The proteins were identified by
searching MS and tandem MS (MS/MS) data of peptides against a
decoy version of the UniProtKB (May 2013) containing 50,807 se-
quences. Carbamidomethylation of cysteines was set as a fixed mod-
ification. N-terminal acetylation, N--Lysine acetylation, oxidation of
methionine, and phosphorylation of serine, threonine, and tyrosine
were set as variable modifications. As many as two missed cleavages
were allowed. The initial allowed mass deviation of the precursor
ion was as high as 6 ppm, and the allowed value for the fragment
mass was as high as 0.5 Da. Mass accuracy of the precursor ions was
improved by the time-dependent recalibration algorithms of Max-
Quant. The “match between runs” option enabled us to match iden-
tifications across samples within a time window of 2 min of the
aligned retention times. The maximum false peptide discovery rate
was specified as 0.01. Label-free quantitation of the data was based
on the LFQ intensities (28). Only proteins that were identified in at
least four of the samples were subjected to quantitation. Missing
values were imputed (width 0.3, downshift 1.8), and the sample data
were normalized using the corresponding median values. T-tests
were applied for testing differences in protein intensities. Significance
of the outliers was calculated by multiple hypothesis testing with a
threshold value of 0.05 (29). The mass spectrometry proteomics data
have been deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE partner repos-
itory with the data set identifier PXD002032.
Lists Overlap—Analysis of the lists of differentially expressed genes
and differentially regulated proteins were performed using R. The list
of the 21 coregulated proteins is reported in Fig. 3. The list of differ-
entially regulated proteins was filtered considering the p value
(0.05). The list of differentially expressed genes (siHMGA1 data
set - GSE35525 (12)) was filtered considering the p value (0.05) and
the log2 fold change (1.00, -1.00).
Functional Analysis—Functional analysis was performed using the
Ingenuity Pathway Analysis tool (Ingenuity® Systems, www.ingenuity.
com), DAVID/EASE tool (30), and Oncomine Pro web tool (31, 32). For
Oncomine analysis, we create our custom concept composed by the
HRS genes. Then our custom concept was analyzed for differential
expression in all available “Cancer versus Normal” data sets and for
differential expression in all available data sets with clinical outcome
information. Functional analysis identified the biological functions/
transcriptional regulators that were most significant to the data sets.
Transcripts were associated with biological functions/transcriptional
regulators in the Ingenuity Knowledge Base. A right-tailed Fisher’s
exact test was used to calculate a p value to determine the probability
that each biological function/transcriptional regulator assigned to the
data set was because of chance alone.
Breast Cancer Data sets, Survival Analysis, and GSA—To obtain a
survival-related signature, screening for survival-related genes was
performed on collection of gene expression data sets using the Ka-
plan-Meier plotter web tool (33) (updated at version 2014). To verify
the correlation of the signature and breast cancer clinical data, KM
curves for the OS, DMFS, and RFS of breast cancer patients, classi-
fied according to the expression of differentially regulated proteins
after HMGA1 silencing (d-A1 and u-A1), the HMGA1 Reduced Signa-
ture (HRS), and the KIFC1, LRRC59, and TRIP13 expression levels,
were obtained using the Gene Expression-Based Outcome for Breast
Cancer Online web tool (GOBO) (33). The samples were split into two
groups according to the quantile expressions of the proposed
signatures/proteins.
qRT-PCR, Wound Healing Assay, and SDS-PAGE and Western
Blot Analyses—These analyses were performed as previously de-
scribed (12). The primer sequences are reported in supplemental
data. The antibodies used in the Western blot analyses were the same
as those used for the immunohistochemistry analyses. Wound heal-
ing assays were performed on 3 ml cell culture plates with cells at
about 80% confluence. Measurements were made calculating the
area in the middle part of the wounds selecting as much as possible
straight and homogeneous zones. Reference points were used to
select starting and ending lines for the area measurements.
Human Specimens—Breast cancer tissues were selected from the
institutional biobank “B. Boerci” at IRCCS Fondazione Salvatore
Maugeri (FSM), where remaining tumor tissues intended for research
purposes were collected from human donors. The use of human
specimens was approved by the FSM Central Ethic Committee, and
informed consent was obtained from all patients. The tumor samples
(KBr1–15) were selected based on a histopathological analysis per-
formed by the Unit of Pathology; 15 triple-negative basal-like, G3
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breast cancers were selected following the immunohistochemistry
analyses. Normal epithelial mammary tissues (NBr) were collected at
the surgical margins of each breast cancer tissue as a control.
Immunohistochemistry—Immunostaining analyses were per-
formed using 5-m-thick formalin-fixed, paraffin-embedded tissue
sections of the breast cancer specimens. Tissues sections of normal
breast from each sample were processed as a control. Epitope re-
trieval was performed in prewarmed pH 6 retrieval buffer in a warm
bath before incubation with rabbit anti-HMGA1 (we used two different
antibodies developed in our laboratory that we named homemade 1
and homemade 2, 1:1.000), anti-KIFC1 (ab172620, 1/100 - Abcam,
Cambridge, UK; ab117535, 1:200 - Abcam), anti-LRRC59 (PA5–
32057, 1:500 - ThermoFisher/Pierce; HPA030827, 1/250 - SigmaAl-
drich), anti-TRIP13 (HPA005727, 1:200 - Sigma-Aldrich; HPA053093,
1/100 - SigmaAldrich) or negative controls. The tumor sections were
incubated with the primary antibody solution overnight at 4 °C. HRP-
mediated antigen detection was carried out with the LSAB™Plus/
HRP kit. The nuclei were counterstained with hematoxylin. The im-
munostaining results were analyzed using a DM1000 microscope
(Leica Microsystems GmbH, Wetzlar, Germany) equipped with LAS
(Leica) Software for image capture and analysis. For the scoring of
positive cells, at least fifty randomly selected regions for each slide
were analyzed. The samples were considered negative when the
staining of the breast tissues displayed the same intensity as their
normal counterparts.
RESULTS
HMGA1-regulated Proteins Detected Using a Label-free
LC-MS/MS Approach—To gain a deeper view of the pro-
teome-wide changes linked to the loss of aggressiveness
caused by HMGA1 silencing (12), we took advantage of high-
throughput proteomics based on a label-free shotgun quan-
titative approach (refer to Fig. 1 for a schematic view of our
experimental workflow). HMGA1 proteins were silenced in
MDA-MB-231 cells using siRNA. The biological effect of
HMGA1 depletion could be observed as the mesenchymal-
epithelial morphological transition, which was clearly visible
upon comparing HMGA1-silenced (siA1_3) and control
(siCTRL) cells (supplemental Fig. S1 and our data reported in
(12)). HMGA1 silencing was verified using quantitative West-
ern blot analyses (supplemental Figs. S2 and S3) and turned
out to be consistent with our previous reported data (12)
The cell lysates (biological triplicate analyses: HMGA1-si-
lenced (siA1_3) versus control (siCTRL) cells) were then
processed according to the MED-FASP procedure, the pep-
tide mixtures were analyzed using LC-MS/MS on a linear ion
trap Orbitrap mass spectrometer (technical duplicate anal-
yses), and the data were processed by MaxQuant. T-tests
were applied for testing differences in protein intensities.
Significance of the outliers was calculated by multiple hy-
pothesis testing with a threshold value of 0.05 (28). Results
of protein identification and quantitation are reported in
supplemental Tables S1 and S2.
FIG. 1. Schematic representation of the experimental workflow.
Silencing of HMGA1 in MDA-MB-231 breast cancer cells led to a
mesenchymal-epithelial transition. The proteins obtained from the
control and HMGA1-silenced cells were extracted and treated with
the FASP protocol prior to MS analysis and label-free quantitation.
The up- and down-regulated sets of proteins were assessed for their
prognostic value. Only the downregulated proteins displayed prog-
nostic significance. These proteins were compared with the gene
expression analyses performed on the same cellular model and only
the common proteins were selected for further analyses. These com-
mon proteins were selected on the basis of their prognostic value and
resulted in a list of 21 proteins, termed the HMGA1 reduced signature
(HRS). Data regarding these 21 proteins were extracted from the
PubMed and Human Protein Atlas resources (www.proteinatlas.org),
with a focus on those proteins with less cancer-related information
and with a differential expression between normal and cancerous
tissues.
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HMGA1 depletion had a profound impact on the MDA-MB-
231 proteome; nearly 17% of the totality of detected proteins
(574 out of 3296, among which 292 proteins were down- and
282 were up-regulated, hereafter called d-A1 and u-A1, re-
spectively) displayed significantly altered expression levels.
Notably, the expression ratio of HMGA1 in the silenced versus
control cells, as determined by mass spectrometry, was in
accordance with that obtained by quantitative Western blot,
thus strengthening the robustness of the MS-based quantita-
tive approaches.
A bird’s eye view of the proteomic alterations obtained
using bioinformatic pathway analysis tools (IPA and DAVID -
Table I and supplemental Tables S3–S5) revealed that the
proteomic alterations caused by HMGA1 silencing had a
strong effect on cell cycle regulation, chromosome structure,
cellular motility mechanism, and protein synthesis. These data
are in strong agreement with our preceding data (12).
An HMGA1 Proteomic Signature Has Prognostic Value in
Breast Cancer—KM plots obtained upon analyzing a collec-
tion of breast cancer gene expression data sets (Kmplot col-
lection v2014) showed that d-A1 proteins represent a molec-
ular signature able to group patients in terms of both OS and
RFS (Fig. 2A and 2B). Moreover, d-A1 proteins were ex-
pressed at higher levels in highly aggressive breast cancers,
such as basal-like, Her2-enriched, and luminal B subtype
(both using HU or PAM50 intrinsic subtypes), as well as ER-
negative and grade 3 tumors (Fig. 2C–2F). On the contrary,
u-A1 proteins did not seem to provide relevant prognostic
information and were not enriched in specific breast cancer
subtypes (supplemental Fig. S4). Therefore, we focused the
bioinformatic and functional analyses on the d-A1 set of pro-
teins (proteins whose expression decreased because of
HMGA1 silencing), which are presumed to be positively reg-
ulated by HMGA1, either by direct or indirect mechanisms.
The Oncomine web tool, which is a cancer microarray da-
tabase and web-based data-mining platform aimed at facili-
tating cancer-related factor discovery from genome-wide ex-
pression analyses (32, 33), confirmed that d-A1 proteins were
significantly up-regulated in several types of human cancer
with respect to normal tissues; moreover, in breast cancer,
these proteins were up-regulated in cases with a worse clin-
ical outcome (Table II), further confirming the prognostic value
of d-A1. Notably, these bioinformatic data are in concordance
both with our previously reported gene array data (12) and
with the literature-reported roles for HMGA1 (15, 34). This
evidence supports the hypothesis that HMGA1-regulated
genes could confer cells an aggressive phenotype, which in
turn could be responsible for a worse clinical outcome.
To obtain a restricted and highly validated list of HMGA1
target proteins, we cross-referenced the proteomic data set
with siHMGA1 data set (12). 60 of the 292 (22%) downregu-
lated proteins in our proteomic data set were also downregu-
lated in the siHMGA1 data set. We chose this strategy be-
cause protein levels can vary for several reasons, not
necessarily linked to mRNA expression levels. Focusing on
those genes which show a downregulation both at mRNA and
protein levels keeps open the possibility of developing in the
future clinical quantitative assays either looking at proteins
(i.e. IHC) or mRNA (i.e. qRT-PCR).
We then performed bioinformatic screening of these 60
proteins for survival-related genes using KM plotter analysis
and a manually curated literature inspection, resulting in a list
of 21 proteins linked to worse outcomes (RFS), which we
referred to as the HMGA1 reduced signature (HRS, Fig. 3A).
The literature inspection highlighted that for 9 members of the
HRS (ATAD2, CSF-1, DLGAP5, KIF11, NCAPG, PGRMC1,
RRM2, TOP2A, and WHSC1 - all of the acronyms are expli-
cated in the abbreviation list), there are conspicuous data
regarding their role in cancer and their potential use as prog-
nostic markers or cancer therapeutic targets (supplemental
Table S6).
Moreover, several HRS members were present in breast
cancer-associated gene signatures, as evidenced by the data
extracted from GeneSigDB, a curated signature database
(supplemental Fig. S5). TOP2A (DNA topoisomerase 2-) and
RRM2 (ribonucleoside-diphosphate reductase subunit M2)
are noteworthy examples of proteins with both a well-estab-
lished role in cancer development and prognostic value
(35, 36).
These observations led us to hypothesize that the HRS
could be strongly enriched in proteins involved in conferring
cells a malignant phenotype. Therefore, we decided to eval-
uate the HRS in two different ways: (1) as a gene signature
with prognostic value and (2) as a source for hypothesis-
driven experiments to unravel unexplored HMGA1-dependent
molecular mechanisms involved in cancer development.
TABLE I
Biological functions associated with down- and up-regulated genes in HMGA1-silenced MDA-MB-231 cells
Database for Annotation, Visualization and Integrated
Discovery (DAVID) Ingenuity Pathway Analysis (IPA)
Functional Annotation Clustering Molecular and Cellular Functions
DOWN UP DOWN UP
Cell cycle Protein biosynthesis Cell cycle Protein synthesis
Chromosome Oxidoreductase Cellular Movement Gene expression
Nucleotide/ATP binding Proteasome Cellular ass. and organiz. Energy production
Macromolecular complex Metabolism DNA repl., recomb. and rep. Lipid metabolism
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The Clinical Performance of the HMGA1 Reduced Signature
(HRS)—High-throughput technologies and genome-wide
screenings have led to the development and use of multigene
assays (MGAs) as tools to aid oncologists in the difficult
decision-making process of treating patients with adjuvant
therapy. Some of these MGAs have already been included in
the major international guidelines for selecting breast cancer
treatments, i.e. Oncotype DX and MammaPrint, and the sci-
entific community is now waiting for definitive results from
ongoing prospective trials regarding their effective clinical
value (37); however, promising evidence suggests that these
MGAs bring significant benefits both for patients and health-
care providers (38). To be effective, MGAs must be standard-
ized, adoptable by nonspecialized laboratories, and less time
consuming than current approaches. Therefore, the general
trend is to start from genome-wide data and end up with a
restricted list of proteins that can be evaluated in qRT-PCR-
or IHC-based assays. Twenty-one proteins obtained using a
FIG. 2. Proteins whose expression is directly proportional to the HMGA1 expression level (d-A1 protein set) represent a signature
associated with the clinical outcome of breast cancer patients and are enriched in specific cancer subtypes. A, B, KM plots for OS and
RFS with regards to the gene expression level (low or high) in a collection of breast cancer gene expression data sets (Kmplot collection v2014)
of the set of proteins that are downregulated following HMGA1 silencing (d-A1 protein set). C–F, Gene set analysis (GSA) of the d-A1 protein
set expression collection of breast cancer gene expression data sets (GOBO collection v2014). Box plots illustrating the expression distribution
of the d-A1 protein set across different cancer subtypes (Hu and PAM50 subtypes), ER-negative and -positive breast cancers, and breast
cancers of different histological grade (1, 2, and 3). The numbers above the charts indicate the patients in each subtype group. The boxplots
show the mean-centered Log2 expression values of the signature across different subtypes/clinical variables.
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cross-validated proteomic-genomic approach comprised our
HRS. This signature, as shown in Fig. 3, shares the same
breast cancer subtype enrichment profile of the entire set of
d-A1 proteins and has almost the same prognostic value as
the entire set of d-A1 proteins. Interestingly, the HRS as well
as d-A1 proteins were identified as independent prognostic
factors for OS, DMSF, and RFS (supplemental Table S7),
which indicates that our selection process eliminated “pas-
senger signal proteins,” thereby significantly shortening the
original protein list.
Several molecular signatures have been defined in the last
decade, and each of them can provide useful prognostic
information, despite very low gene/protein overlap. A com-
parative evaluation of the HRS with respect to other molecular
signatures (Table III) shows that the HRS overlaps with at best
less than 50% of its composition. In other words, our ap-
proach led us to obtain a much smaller but quite unique
signature, which is not simply a subset of already known
breast cancer signatures.
Translating Proteomic Into Functional Data: The As-yet-
unexplored Role of Selected HRS Members in Cancer and
Their Potential Use as Breast Cancer Biomarkers—Genome-
and proteome-wide screenings are typically adopted to un-
ravel unexplored functional implications of a specific protein.
To exploit our protein list in this direction, we adopted a
prioritization criterion based on selecting those components
that are less characterized from a cancer-related point of view
(see supplemental Table S6) and whose Human Protein Atlas
(www.proteinatlas.org) IHC data indicate their use as potential
cancer biomarkers because their expression is higher in can-
cer cells with respect to normal counterparts (Fig. 4). We
selected six genes as potential candidates for further explo-
ration, i.e. BAZ1B, DDX18, KIFC1, LRRC59, RPRD1A, and
TRIP13, and among these, we arbitrarily selected KIFC1,
LRRC59, and TRIP13. As a first step, we confirmed that the
expression of these three genes was linked to HMGA1 ex-
pression levels in MDA-MB-231 cells both by qRT-PCR and
western-blot analyses using two different siRNA molecules
targeting HMGA1 (Fig. 5A). We confirmed these data also in
the triple-negative MDA-MB-157 breast cancer cell line (sup-
plemental Fig. S6). Importantly, we confirmed the link be-
tween the expression of HMGA1 and KIFC1, LRRC59, and
TRIP13 in vivo by evaluating their expression in triple-negative
G3 breast cancer specimens, either expressing [n  10; 2
invasive lobular carcinoma (ILC), 3 ductal carcinoma in situ
(DCIS), 4 invasive ductal carcinoma (IDC), and 1 mixed DCIS/
IDC] or not expressing HMGA1 proteins [n  5; 5 invasive
ductal carcinoma (IDC)]. The results reported in Fig. 5B and in
supplemental Fig. S7 clearly demonstrate a strong correlation
between the expression of HMGA1 and these three proteins.
Indeed, in HMGA1-positive specimens, the concordances
with HMGA1 expression for the three proteins were as fol-
lows: LRRC59, 9/10; KIFC1, 7/7; and TRIP13, 7/10. In
HMGA1-negative specimens the concordances were as fol-
lows: LRRC59, 4/5; KIFC1, 3/4; and TRIP13, 5/5. Overlapping
results were obtained using a different set of antibodies on the
same tissue specimens (supplemental Fig. S8 - concordance
in HMGA1-positive samples: LRRC59, 7/7; KIFC1, 7/7;
TRIP13, 6/7 - concordance in HMGA1-negative samples:
LRRC59, 2/4; KIFC1, 3/4, TRIP13, 4/4). Western blot analyses
assessing the specificities of the used antibodies are reported
in supplemental Fig. S9 and S10.
Because one of the main effects attainable by HMGA1
silencing in basal-like TNBC cells is an evident morphological
transition from a mesenchymal phenotype toward an epithe-
lial one, typically accompanied by a strong impairment of cell
motility (12), we assessed whether KIFC1, LRRC59, and
TRIP13 partially contribute to these HMGA1-linked effects in
MDA-MB-231 cells. Using siRNA, we silenced the expression
of these three genes and performed wound healing assays
and evaluated cell morphology in parallel (Fig. 6). As observed
in Fig. 6A, there was an evident transition from a mesenchy-
mal phenotype toward an epithelial one accompanying each
of the three gene silencing experiments. Moreover, the wound
healing experiments (Fig. 6B) clearly demonstrated that the
silencing of KIFC1, LRRC59, and TRIP13 strongly impaired
wound closure, thus indicating that these three genes have an
impact on cell motility pathways. Noteworthy, the silencing of
these three proteins has the same effects in the in the triple-
negative MDA-MB-157 breast cancer cell line (supplemental
Fig. S11). The acquisition of mesenchymal features and in-
creased cell motility are essential steps during the process of
tumor metastasis. Therefore, the experimental results ob-
tained by silencing the expression of these three genes
TABLE II
Oncomine analysis of down-regulated proteins (d–A1 protein set)
Over-/Under-expression
in cancer tissues
Worst outcome
Over Under Over Under
Bladder 5
Brain and CNS 10 1 5
Breast 8 1 33 1
Cervical 4
Colorectal 19 4 1
Oesophageal 2
Gastric 6 1
Head and Neck 17 1 1
Kidney 3 4
Leukaemia 1 4 1 1
Liver 4
Lung 16 9 2
Lymphoma 4 7 8
Melanoma 2 3
Myeloma 3 5
Other 14 2 2
Ovarian 6 5 3
Pancreatic 3 1
Prostate 2 3 3
Sarcoma 12 1
Total 140 8 84 21
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FIG. 3. The HMGA1 reduced signature (HRS) is associated with the clinical outcome of breast cancer patients and is enriched in
specific cancer subtypes. A, List of proteins in the HRS. B–D, KM plots for OS, RFS, and DMFS with regards to HRS gene expression level
(low or high) a collection of breast cancer gene expression data sets (Kmplot collection v2014). E–H, GSA of HRS expression collection of
breast cancer gene expression data sets (GOBO collection v2014). Box plots illustrating the expression distribution of the HRS across different
cancer subtypes (Hu and PAM50 subtypes), ER-negative and -positive breast cancers, and breast cancers of different histological grade (1,
2, and 3). The numbers above the charts indicate the patients in each subtype group. The boxplots show the mean-centered Log2 expression
values of the signature across different subtypes/clinical variables.
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FIG. 4. The expression levels of HRS proteins in breast tissues (cancer versus normal) obtained using the publicly available Human
Protein Atlas resource. Each member of the HRS was searched in the Human Protein Atlas resource (cancer tissues - breast cancer; normal
tissues - glandular cells), and the percentages of cases showing different levels of antibody staining (high, medium, low, and not detected) are
reported as stacked column charts. The antibody identification code together with the number (n) of cancer and normal cases analyzed are
reported on the right. Some of the proteins are reported twice or three times according to the number of antibodies used. For CSF1 and SMC2,
no data are available.
TABLE III
Overlap of selected breast cancer gene signatures with the HRS
Signature PubMed ID N genes Overlap p values Topic
ABBA 21082037 111 6 1.22  1011 Metasignatures
CRAWFORD 18427120 377 8 5.24  1011 BRD4 chromatin modifier
WONG-ESC 18397753 335 7 7.84  1010 Cancer stem cells
CARTER 16921376 70 4 7.79  1009 Chromosomal instability
MA 12714683 30 3 2.18  1008 IDC vs. DCIS
WHITFIELD 12058064 587 7 6.26  1008 Cell cycle
RHODES 15184677 67 3 5.95  1007 Metasignatures
SOTIRIOU-GGI 16478745 90 3 1.95  1006 G2 classification
META-PCNA 22028643 129 3 8.21  1006 Cell cycle
PAWITAN 16846532 46 2 1.36  1005 Intrinsic molecular signature
SAAL 17452630 162 3 2.02  1005 PTEN
CHANG 14737219 355 2 5.42  1003 TAF
BEN-PORATH-EXP1 18443585 367 2 5.94  1003 Cancer stem cells
HUA 19563758 1345 2 1.55  1001 ER1 and RARs
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prompted us to evaluate their potential clinical value. By in-
terrogating a breast cancer gene expression data set (GOBO
data set), we obtained the expression of KIFC1, LRRC59, and
TRIP13 genes for tumor samples stratified according to HU
and PAM50 subtypes, ER status, and histological grade. We
also evaluated the OS, DMFS, and RFS KM curves (Kmplot
data set, v2014). As shown in Fig. 7A, KIFC1 and TRIP13
demonstrated more interesting results from a clinical point of
view with respect to LRRC59. Indeed, these two genes were
expressed at higher levels in the more aggressive subtypes
(i.e. basal-like, Her2-overexpressing, and luminal B), in ER-
negative tumors, and in grade 3 classified tumors. Moreover,
KM curves (panel B) clearly indicated that both KIFC1 and
TRIP13 outperformed LRRC59 in terms of clinical value with
regard to OS, DMFS, and RFS. Furthermore, multivariate
analyses considering their expression levels together with size
FIG. 5. The expression of KIFC1, LRRC59, and TRIP13 is linked to HMGA1. MDA-MB-231 cells were treated with control (siCTRL) or
HMGA1-targeting siRNAs (siA1_1 and siA1_3) for 72 h. A, mRNA and protein expression levels of the indicated genes were analyzed by
qRT-PCR and Western blot. Gene expression levels in HMGA1-silenced cells were compared with that of siCTRL cells. GAPDH was used for
normalization. Representative WB analyses are shown together with red ponceau stained membranes to verify total protein normalization. The
histogram graphs relative to Western blot analyses were obtained using densitometric analyses (siCTRL versus siA1_1 and siA1_3). The bars
indicate the mean 	 S.D. (n  3). Statistical significance was assessed with Student’s t test (*: p  0.05; **: p  0.01; ***: p  0.001). B,
Immunohistochemistry analyses performed on breast cancer specimens (IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ;
IDC/DCIS, mixed IDC and DCIS) positive for KIFC1, LRRC59, and TRIP13 and HMGA1.
A Proteomic HMGA1-linked Signature in Breast Cancer
118 Molecular & Cellular Proteomics 15.1
(20 mm), age (50 years), grade (G3), node status (nega-
tive), and ER status (positive) indicated that they represent
independent prognostic factors for OS, DMSF, and RFS and
that KIFC1 and TRIP13 outperformed LRRC59 (supplemental
Table S8). These findings were further supported by interro-
gating the Oncomine cancer microarray database for the ex-
pression of these three genes in twenty different cancer types
(supplemental Table S9). KIFC1 was overexpressed in 42 out
of 459 analyses (cancer tissue versus normal tissue) and
TRIP13 in 69 out of 467 analyses (fold change threshold: 2; p
value threshold: 1  104). Moreover, the cancer type more
enriched for KIFC1 overexpression was found to be breast
cancer (11), followed by lung (7) and prostate cancer (4). On
the other hand, the cancer type showing more results for
TRIP13 overexpression was colorectal cancer (15), followed
by lung (9) and sarcoma (7).
DISCUSSION
Exploiting a label-free shotgun quantitative proteomic ap-
proach in which the results were cross-referenced with gene
array data, we obtained a list of 60 HMGA1-linked genes
downregulated at both the mRNA and protein level in a basal-
like TNBC cell line. Following bioinformatic filtering for clini-
cally relevant genes obtained using breast cancer gene ex-
pression data sets, we obtained a panel of 21 factors that we
referred to as the HMGA1 reduced signature (HRS), whose
expression was linked to poor prognosis in cancer. This sig-
nature showed prognostic value, demonstrated the validity of
our approach in shortening the original molecular signature,
and highlighted a multifaceted role of HMGA1 proteins in
regulating tumor aggressiveness.
Molecular signatures not only represent a clinical tool to aid
clinicians in decision-making processes but can also provide
clues that highlight the involvement of new genes in specific
pathologies. As often occurs in large-scale screenings to
identify molecular signatures with clinically relevant features,
many of the genes composing these signatures already have
a clear connection with the specific pathology taken into
consideration. On the contrary, those genes not yet charac-
terized represent potential novel molecules that could be
specifically targeted or that could provide novel insight into
the molecular mechanisms of the pathology onset. In this
work, we focused on three underexplored proteins (KIFC1,
TRIP13, and LRRC59). We demonstrated that these proteins
lie downstream of HMGA1 (both in a cellular model and in
clinical specimens) and are involved in the modulation of cell
motility, which is one of the first characteristics a cancer cell
must acquire to disseminate.
● KIFC1 (kinesin family member C1) is a minus end-directed
motor protein of the kinesin-14 family, which is involved in the
process of centrosome clustering in cancer cells that display
amplified centrosomes (39). Very little is known regarding the
involvement of this protein with other aspects of cancer pro-
gression, albeit that it constitutes a potential prognostic
FIG. 6. The silencing of KIFC1, LRRC59, and TRIP13 causes a
mesenchymal-epithelial morphological transition in MDA-MB-
231 cells that is accompanied by a strong impairment of cell
motility.MDA-MB-231 cells were treated with control siRNA (siCTRL)
or siRNA targeting KIFC1, LRRC59, and TRIP13 (siKIFC1, siLRRC59,
and siTRIP13). After 72 h, the cells were evaluated for their morphol-
ogy (optical microscope) (A) and motility using wound healing assays
(B). The scale bar represents 50 m. The bars indicate the mean 	
S.D. (n  3, each point is a technical duplicate). Statistical signifi-
cance was assessed with Student’s t test (*: p 0.05; **: p 0.01; ***:
p  0.001). The evaluation of silencing efficacy was performed by
lysing the cells in SDS-sample buffer after the wound healing assay
and analyzing the expression of the three proteins by Western blot.
Representative WB analyses are shown together with red ponceau
stained membranes to verify total protein normalization. Relative pro-
tein expression levels were obtained by densitometric analyses of WB
analyses (siCTRL versus siKIFC1, siLRRC59, and siTRIP13). The bars
indicate the mean 	 S.D. (n  3). Statistical significance was as-
sessed with Student’s t test (*: p  0.05; **: p  0.01; ***: p  0.001).
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FIG. 7. KIFC1 and TRIP13 are associated with the clinical outcome of breast cancer patients and are enriched in specific cancer
subtypes. A, GSA of KIFC1, LRRC59, and TRIP13 expression in collection of breast cancer gene expression data sets (GOBO collection
v2014). Box plots illustrate the expression distribution of KIFC1, LRRC59, and TRIP13 across different cancer subtypes (Hu and PAM50
subtypes), ER-negative and -positive breast cancers, and breast cancers of different histological grade (1, 2, and 3). The numbers above the
charts indicate the patients in each subtype group. The boxplots show the mean-centered Log2 expression values of the signature across
different subtypes/clinical variables. B, KM plots for OS, RFS, and DMFS with regards to the KIFC1, LRRC59, and TRIP13 gene expression
level (low or high) in a collection of breast cancer gene expression data sets (Kmplot collection v2014).
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marker for ovarian adenocarcinoma (40) and was found to be
associated with metastatic spread to the brain of nonsmall
cell lung cancer (41). Notably, a drug targeting KIFC1 has
been already developed (AZ82) and tested in cancer cells, and
this drug was demonstrated to specifically affect the survival
of cancer cells with amplified centrosomes (42). Centrosomes
are frequently amplified in cancer cells, leading to mitotic
defects that cause karyotypic changes arising from chromo-
some mis-segregation (43), and centrosome clustering is a
stratagem used by cancer cells to limit catastrophic effects of
multipolar mitosis that is usually linked to unsustainable levels
of aneuploidy; however, centrosome amplification and clus-
tering also fuel cell motility. Indeed, centrosomes are “micro-
tubule organizing centers” that are responsible for the proper
organization of the Golgi apparatus during interphase, which
in turn provides cells with a directional flux of vesicles in-
volved in the transport of migration promoting factors to the
leading edge (44).
● TRIP13 (thyroid hormone receptor interacting protein 13)
is an AAA-ATPase involved both in mitotic checkpoint regu-
lation (45) and the regulation of meiotic recombination and
chromosome structure development (46). Very recently, it has
been demonstrated that TRIP13 overexpression is associated
with enhanced nonhomologous end joining (NHEJ) activity,
leading to error accumulation and development of chemore-
sistance (47). TRIP13 also appears in cancer-associated mo-
lecular signatures (48, 49), therefore underlining its potential
role in cancer.
● LRRC59 (leucine-rich repeat containing 59) is an ER-
anchored protein and an intracellular binding partner for fibro-
blast growth factor 1 (FGF1), and this protein is essential for
the noncanonical signaling pathway of FGF1 (50). Indeed,
FGF1, in addition to the signaling cascade activated by bind-
ing to its high-affinity cell-surface receptors (FGFR1–4), can
be translocated via an LRRC59-dependent mechanism di-
rectly into the nucleus where it has direct regulatory functions
(51).
Consistent with this information and with our experimental
evidence, bioinformatic evaluation of the clinical predictive
performance of these three genes clearly indicates their con-
nection with a worse outcome of the cancer pathology, es-
pecially in regards to KIFC1 and TRIP13.
HMGA1 is a multifunctional protein whose overexpression
perturbs different processes leading to neoplastic transforma-
tion. This feature, together with the fact that it is highly ex-
pressed in cancer cells, but nearly undetectable in normal
tissues, suggests that it could be an ideal chemotherapeutic
target (52–55); however, the identification of its downstream
functional effectors could also provide unexplored opportuni-
ties to target cancer cells.
In conclusion, despite intrinsic limitations of this study (i.e.
data obtained by analyzing one single human triple-negative
breast cancer cell line and the lack of true normal breast
tissue specimens for the evaluation of protein expression in
IHC analyses), our study allowed us to define a short molec-
ular signature linked to HMGA1 expression that has prognos-
tic value in breast cancer and that could be eventually used
for developing an RT-PCR based tests. More interestingly, our
data allowed to determine a previously unknown role for three
proteins in regulating cell motility and possibly the entire
process leading to the acquisition of metastatic features. Two
of these proteins (KIFC1 and TRIP13) display enzymatic ac-
tivity, thus opening the possibility to develop specific drugs
for targeted therapies. These findings assume relevance par-
ticularly in regards to TNBC, a unique and extremely hetero-
geneous breast cancer form for which cytotoxic chemother-
apy still remains a less than ideal option because no targeted
therapies are available (1). Moreover, gene expression data
sets highlight that the overexpression of these two factors is
not limited to breast cancer; therefore, these factors should
be further investigated as they may be valuable new potential
broad-spectrum biomarkers to be exploited in IHC prognostic
evaluations and also as cancer specific targets.
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